KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Payables (2016 - 2025)

Historic Payables for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to $20.9 million.

  • Halozyme Therapeutics' Payables rose 10391.26% to $20.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $20.9 million, marking a year-over-year increase of 10391.26%. This contributed to the annual value of $20.9 million for FY2025, which is 10391.26% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Payables stood at $20.9 million for Q4 2025, which was up 10391.26% from $15.4 million recorded in Q3 2025.
  • Halozyme Therapeutics' 5-year Payables high stood at $20.9 million for Q4 2025, and its period low was $535000.0 during Q1 2021.
  • Its 5-year average for Payables is $11.8 million, with a median of $12.3 million in 2022.
  • Per our database at Business Quant, Halozyme Therapeutics' Payables plummeted by 9356.97% in 2021 and then skyrocketed by 104815.06% in 2022.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Payables stood at $1.5 million in 2021, then surged by 1048.15% to $17.7 million in 2022, then crashed by 33.22% to $11.8 million in 2023, then decreased by 13.26% to $10.2 million in 2024, then surged by 103.91% to $20.9 million in 2025.
  • Its last three reported values are $20.9 million in Q4 2025, $15.4 million for Q3 2025, and $18.7 million during Q2 2025.